Overview
- Topline ARTISTRY-2 results show switching virologically suppressed adults from Biktarvy to once‑daily BIC/LEN maintained viral suppression at Week 48, meeting the primary noninferiority endpoint.
- The primary measure was the proportion of participants with HIV-1 RNA at or above 50 copies per milliliter at Week 48 in a randomized, double‑blind study.
- Participants were assigned in a 2:1 ratio to switch to BIC/LEN or remain on Biktarvy, supporting evaluation of a single‑tablet maintenance option.
- Investigators reported the regimen was generally well tolerated with no new or significant safety concerns identified in the trial.
- Gilead will combine ARTISTRY-2 with prior ARTISTRY-1 data for presentations at a scientific congress and for regulatory submissions, and the fixed‑dose BIC/LEN remains investigational.